REVIEW Nebivolol is a chiral, selective, third-generation beta1-receptor antagonist used in the treatment of hypertension and chronic heart failure. It blocks activation of adrenergic receptors by epinephrine, reversing its effects and lowering heart rate and blood pressure. It has additional nitric oxide-mediated vasodilating and antioxidant properties, along with a favorable metabolic profile.
Noe, Christian R.; Jasic, Muhamed; Kollmann, Hermann; Lachmann, Bodo Process for preparation of Nebivolol using 6-fluoro-3,4-dihydrobenzopyran-2-carboxaldehyde cyanohydrins. PCT Int. Appl. (2007), WO 2007009143 A2 20070125.
Khamar, Bakulesh Mafatlal; Thakor, Indrajit; Patel, Mahesh; Jadav, Kalpesh; Parikh, Ankur; Joshi, Atul Chhotalal; Ponnaiah, Ravi; Modi, Indravadan Ambalal An improved process for the preparation of nebivolol hydrochloride Eur. Pat. Appl. (2010), EP 2163551 A1 20100317.
Maragni, Paolo; Michieletto, Ivan; Volpicelli, Raffaella; Soriato, Giorgio; Foletto, Johnny; Cotarca, Livius; Verzini, Massimo Process for preparing nebivolol PCT Int. Appl. (2010), WO 2010049455 A1 20100506.
Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.